ZÖLLER-KIPPER works together with the diagnostics company Mainz Biomed N.V. as part of its occupational health management programme.

According to the World Cancer Research Fund International, bowel cancer is the third most common cancer worldwide. As early diagnosis of the disease is crucial for successful treatment, ZÖLLER-KIPPER has decided to support its 350 employees in early detection. A small step that can save lives.

Cancer prevention made easy: early detection test is well received by employees

With new test kits, employees can now have a bowel cancer screening with little effort. Irina Riffel, Head of HR at ZÖLLER-KIPPER, aptly describes the simple registration and use of the test kits: „Our employees can easily access the patient portal, request a kit and receive their results within five days. Feedback on the process has been positive and we are very pleased to be able to offer this test, as early detection and diagnosis of colorectal cancer is crucial for better treatment options and outcomes. The health and well-being of our employees is our top priority.“

An important step towards the future:

The results are promising. This not only benefits the company’s own employees. By using the early detection tests approved in Europe, the company is making an important contribution to the approval of the kits in the USA. An important step towards the future, as Guido Baechler, CEO of Mainz Biomed, emphasises: „We are very pleased with the initial results, as they show what the future holds for patients when they have better access to easy-to-use, convenient and affordable screening options.“